Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia

Ítems similars

• Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin
  per: Jones, Angus G, et al.
  Publicat: (2012)
• Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic
  per: Hope, SV, et al.
  Publicat: (2016)
• Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia
  per: Hope, Suzy V., et al.
  Publicat: (2018)
• Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study
  per: Oram, Richard A, et al.
  Publicat: (2013)
• Markers of beta cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes
  per: Jones, Angus G, et al.
  Publicat: (2015)